Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck

Authors: W Budach, T Hehr, V Budach, C Belka, K Dietz

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Former meta-analyses have shown a survival benefit for the addition of chemotherapy (CHX) to radiotherapy (RT) and to some extent also for the use of hyperfractionated radiation therapy (HFRT) and accelerated radiation therapy (AFRT) in locally advanced squamous cell carcinoma (SCC) of the head and neck. However, the publication of new studies and the fact that many older studies that were included in these former meta-analyses used obsolete radiation doses, CHX schedules or study designs prompted us to carry out a new analysis using strict inclusion criteria.

Methods

Randomised trials testing curatively intended RT (≥60 Gy in >4 weeks/>50 Gy in <4 weeks) on SCC of the oral cavity, oropharynx, hypopharynx, and larynx published as full paper or in abstract form between 1975 and 2003 were eligible. Trials comparing RT alone with concurrent or alternating chemoradiation (5-fluorouracil (5-FU), cisplatin, carboplatin, mitomycin C) were analyzed according to the employed radiation schedule and the used CHX regimen. Studies comparing conventionally fractionated radiotherapy (CFRT) with either HFRT or AFRT without CHX were separately examined. End point of the meta-analysis was overall survival.

Results

Thirty-two trials with a total of 10 225 patients were included into the meta-analysis. An overall survival benefit of 12.0 months was observed for the addition of simultaneous CHX to either CFRT or HFRT/AFRT (p < 0.001). Separate analyses by cytostatic drug indicate a prolongation of survival of 24.0 months, 16.8 months, 6.7 months, and 4.0 months, respectively, for the simultaneous administration of 5-FU, cisplatin-based, carboplatin-based, and mitomycin C-based CHX to RT (each p < 0.01). Whereas no significant gain in overall survival was observed for AFRT in comparison to CFRT, a substantial prolongation of median survival (14.2 months, p < 0.001) was seen for HFRT compared to CFRT (both without CHX).

Conclusion

RT combined with simultaneous 5-FU, cisplatin, carboplatin, and mitomycin C as single drug or combinations of 5-FU with one of the other drugs results in a large survival advantage irrespective the employed radiation schedule. If radiation therapy is used as single modality, hyperfractionation leads to a significant improvement of overall survival. Accelerated radiation therapy alone, especially when given as split course radiation schedule or extremely accelerated treatments with decreased total dose, does not increase overall survival.
Appendix
Available only for authorised users
Literature
1.
Baumann M, Bentzen SM, Ang KK: Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol. 1998, 46: 127-30. 10.1016/S0167-8140(97)00173-4.CrossRefPubMed
2.
Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997, 37: 259-67. 10.1016/S0360-3016(96)00511-1.CrossRefPubMed
3.
Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H: Hyperfractionation: where do we stand?. Radiother Oncol. 1997, 43: 1-21. 10.1016/S0167-8140(97)01911-7.CrossRefPubMed
4.
Dubben HH: Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours. Radiother Oncol. 1994, 32: 197-200. 10.1016/0167-8140(94)90018-3.CrossRefPubMed
5.
Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000, 355: 949-55.CrossRefPubMed
6.
Bourhis J, Amand C, Pignon JP, on behalf of the MACH-NC Collaborative Group: Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol., ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004, 22 (No 14S (July 15 Supplement)): 5505-
7.
Eschwege F, Sancho-Garnier H, Gerard JP, Madelain M, DeSaulty A, Jortay A, Cachin Y: Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: experience of the European Organization for Research and Treatment of Cancer. NCI Monogr. 1988, 6: 275-278.PubMed
8.
Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, Friedman MA, Kohler M, McWhirter K, Carter SK: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol. 1987, 5: 1410-1418.PubMed
9.
Haffty BG, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, Rockwell S, Sartorelli AC, Fischer JJ: Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol. 1997, 15: 268-276.PubMed
10.
Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q: A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol. 2001, 60: 113-122. 10.1016/S0167-8140(01)00347-4.CrossRefPubMed
11.
Weissler MC, Melin S, Sailer SL, Qaqish BF, Rosenman JG, Pillsbury HC: Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1992, 118: 806-810.CrossRefPubMed
12.
Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD: Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005, 23: 1125-1135. 10.1200/JCO.2005.07.010.CrossRefPubMed
13.
Skladowski K, Maciejewski B, Golen M, Pilecki B, Przeorek W, Tarnawski R: Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer – report on 3-year tumour control and normal tissue toxicity. Radiother Oncol. 2000, 55: 101-110. 10.1016/S0167-8140(00)00139-0.CrossRefPubMed
14.
Zakotnik B, Smid L, Budihna M, Lesnicar H, Soba E, Furlan L, Zargi M: Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys. 1998, 41: 1121-1127. 10.1016/S0360-3016(98)00157-6.CrossRefPubMed
15.
Salvajoli JV, Morioka H, Trippe N, Kowalski LP: A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 1992, 249: 211-215. 10.1007/BF00178472.CrossRefPubMed
16.
Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M: A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997, 44: 123-36. 10.1016/S0167-8140(97)00094-7.CrossRefPubMed
17.
Okunieff P, Morgan D, Niemierko A, Suit HD: Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys. 1995, 32: 1227-1237. 10.1016/0360-3016(94)00475-Z.CrossRefPubMed
18.
Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1990, 19: 1347-50.CrossRefPubMed
19.
Mendenhall WM, Parsons JT: Management of stages III and IV head and neck cancer. Int J Radiat Oncol Biol Phys. 1990, 19: 1627-1628.CrossRefPubMed
20.
Willers H, Liertz-Petersen C, Dubben HH, Beck-Bornholdt HP: Outcome of hyperfractionated radiation therapy in randomized clinical trials. Int J Radiat Oncol Biol Phys. 1998, 40: 257-259.CrossRefPubMed
21.
Williams MV, Denekamp J, Fowler JF: Review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985, 11: 87-96.CrossRefPubMed
22.
Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988, 27: 131-146.CrossRefPubMed
23.
Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997, 44: 111-121. 10.1016/S0167-8140(97)00079-0.CrossRefPubMed
24.
Lo TC, Wiley AL, Ansfield FJ, Brandenburg JH, Davis HL, Gollin FF, Johnson RO, Ramirez G, Vermund H: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. American Journal of Roentgenology. 1976, 126: 229-235.CrossRefPubMed
25.
Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. Journal of Clinical Oncology. 1994, 12: 2648-2653.PubMed
26.
Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol. 1997, 43: 29-37. 10.1016/S0167-8140(97)00048-0.CrossRefPubMed
27.
Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003, 21: 92-98. 10.1200/JCO.2003.01.008.CrossRefPubMed
28.
Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, Wahid I, Turkan S, Tatsuzaki H, Dinshaw KA, Overgaard J: Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol. 2003, 67: 17-26. 10.1016/S0167-8140(03)00020-3.CrossRefPubMed
29.
Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000, 88: 876-883. 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y.CrossRefPubMed
30.
Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S: Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy – a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003, 55: 78-92. 10.1016/S0360-3016(02)03792-6.CrossRefPubMed
31.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003, 55: 93-98. 10.1016/S0360-3016(02)03819-1.CrossRefPubMed
32.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999, 91: 2081-2086. 10.1093/jnci/91.24.2081.CrossRefPubMed
33.
Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000, 18: 1458-1464.PubMed
34.
Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998, 338: 1798-1804. 10.1056/NEJM199806183382503.CrossRefPubMed
35.
Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998, 16: 1318-1324.PubMed
36.
Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001, 50: 1161-1171. 10.1016/S0360-3016(01)01544-9. Erratum in: Int J Radiat Oncol Biol Phys 2001, 51:569CrossRefPubMed
37.
Dobrowsky W, Naude J: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol. 2000, 57: 119-124. 10.1016/S0167-8140(00)00233-4.CrossRefPubMed
38.
Keane TJ, Cummings BJ, O'Sullivan B, Payne D, Rawlinson E, MacKenzie R, Danjoux C, Hodson I: A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys. 1993, 25: 613-618.CrossRefPubMed
39.
Corvo R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, Pallestrini E, Merlano M, Vitale V, Rosso R: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer. 2001, 92: 2856-2867. 10.1002/1097-0142(20011201)92:11<2856::AID-CNCR10132>3.0.CO;2-6.CrossRefPubMed
40.
Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996, 88: 583-589.CrossRefPubMed
41.
Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S: Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy – a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003, 55: 78-92. 10.1016/S0360-3016(02)03792-6.CrossRefPubMed
42.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000, 48: 7-16. 10.1016/S0360-3016(00)00663-5.CrossRefPubMed
43.
Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, Van Glabbeke M: The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol. 1995, 35: 91-99. 10.1016/0167-8140(95)01538-R.CrossRefPubMed
44.
Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003, 362: 933-940. 10.1016/S0140-6736(03)14361-9. Erratum in: Lancet. 2003, 362:1588CrossRefPubMed
45.
Pinto LH, Canary PC, Araujo CM, Bacelar SC, Souhami L: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991, 21: 557-562.CrossRefPubMed
46.
Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S, Bolla M: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992, 25: 231-241. 10.1016/0167-8140(92)90242-M.CrossRefPubMed
Metadata
Title
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck
Authors
W Budach
T Hehr
V Budach
C Belka
K Dietz
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-28

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

Research article

Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy

Research article

Understanding the attitudes of the elderly towards enrolment into cancer clinical trials

Research article

Clinical management of women with metastatic breast cancer: a descriptive study according to age group

Research article

Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

Research article

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits